CION Ameerpet
Almost everything written about ovarian cancer describes a disease of women past fifty. Germ cell tumours are not that disease. They occur in girls and young women, they grow quickly, they are usually caught while still in one ovary — and they respond to treatment better than almost any other cancer of the ovary.
A germ cell ovarian tumour starts in the cells that would have become eggs, rather than in the surface lining of the ovary. That single fact explains nearly everything that follows: these tumours appear decades earlier than the ovarian cancer most people have heard of, they grow quickly, and they are usually still confined to one ovary at the point they are found.
Almost everything written about ovarian cancer — the vague symptoms, the CA-125 blood test, the extensive surgery, the sobering survival figures — describes epithelial ovarian cancer, a disease largely of women past fifty. Our complete guide to ovarian cancer is built around that far commoner condition. If a nineteen-year-old has been told she has an ovarian germ cell tumour, most of that material is not about her.
The honest headline here is a good one, and it is worth saying before anything else. Malignant germ cell tumours divide fast, which sounds frightening and is precisely why chemotherapy works so well against them. Cure is the expected goal rather than the exception, and the standard operation removes the affected ovary while leaving the uterus and the other ovary in place — even when the tumour has spread beyond the ovary.
Not the surface epithelium. That is why they arrive decades earlier than the usual ovarian cancer and behave nothing like it.
Most are confined to a single ovary when found — largely because they grow fast enough to cause symptoms while still small.
Chemotherapy targets rapidly dividing cells. The feature that looks alarming on a scan is the reason treatment works.
Before effective combination chemotherapy existed, a malignant ovarian germ cell tumour was frequently fatal in an otherwise healthy young woman. The platinum-based regimens developed for testicular cancer in the 1970s changed that completely, and malignant germ cell tumours of the ovary became among the most curable of all solid cancers. That is why standard management is fertility-sparing surgery — removing the affected ovary and tube while leaving the uterus and the opposite ovary in place — even when disease has spread beyond the ovary. In this disease, treatment is planned around a young woman's whole life rather than the tumour alone. Source: WHO Classification of Tumours, Female Genital Tumours (5th ed.); NCCN Guidelines, Ovarian Cancer — Less Common Histopathologies.
Your pathology report names one of these. Each behaves differently enough that the name on the report changes the plan.
| Tumour type | Typical features | What it means for treatment |
|---|---|---|
| Dysgerminoma | The commonest malignant germ cell tumour of the ovary. Usually one ovary, most often in the teens and twenties. LDH is frequently raised. | Exceptionally sensitive to chemotherapy, and fertility-sparing surgery is standard. Dysgerminoma in detail. |
| Immature teratoma | Contains immature, embryonic-looking tissue, and is graded 1 to 3 by how much of it the pathologist sees. AFP may be raised. | The grade drives whether chemotherapy is needed after surgery. Immature teratoma in detail. |
| Yolk sac tumour | Also called endodermal sinus tumour. Grows quickly, often in the first two decades of life. AFP is characteristically raised. | Chemotherapy after surgery is usual, and AFP is followed closely to confirm it is working. |
| Embryonal carcinoma | Uncommon in the ovary. Can raise both AFP and beta-hCG, and sometimes causes irregular bleeding or early puberty. | Managed like the other non-dysgerminoma tumours, with chemotherapy after surgery. |
| Non-gestational choriocarcinoma | Rare. Produces beta-hCG, so it can be mistaken for a pregnancy on a urine test. | Needs specialist input to separate it from the pregnancy-related tumour of the same name, which is treated differently. |
| Mixed germ cell tumour | Contains more than one of the above within the same tumour. Commoner than several of the pure types. | The most aggressive component present decides the treatment plan and which markers are followed. |
| Mature cystic teratoma (dermoid) | Benign, and by far the commonest ovarian germ cell tumour of all. Contains mature tissue such as fat, hair or teeth. | Not cancer. Removed if it is large, painful or at risk of twisting; no chemotherapy is involved. |
*If the report names more than one component, that is a mixed tumour, and the plan follows whichever component behaves worst rather than the one listed first.
Each of these is a place where applying general ovarian cancer practice to a young woman produces the wrong answer.
Germ cell tumours secrete different substances from epithelial cancers. The markers that matter are alpha-fetoprotein (AFP), beta human chorionic gonadotrophin (beta-hCG) and lactate dehydrogenase (LDH). CA-125 can be entirely normal alongside an active germ cell tumour, so a normal result is not the reassurance it is often taken to be.
There is a timing point that matters more than most people realise: these markers should ideally be drawn before surgery. A pre-operative level gives everyone a baseline, and the speed at which it falls afterwards is one of the clearest signals that treatment is working. Once the tumour is out, that information cannot be recovered.
A mass that has visibly enlarged between two scans is genuinely characteristic of this group of tumours, and it is frightening to see. But rapid division is exactly what chemotherapy exploits, which is why these tumours respond so much better than the slower-growing cancers of older women.
Fast growth has one practical consequence worth knowing: a rapidly enlarging ovarian mass is more likely to twist on its own blood supply. Sudden, severe, one-sided pelvic pain with vomiting is a surgical emergency and should be taken to a hospital rather than waited out.
In most ovarian cancers, preserving fertility is a careful exception argued for case by case. Here it is the default. Standard practice removes the affected ovary and fallopian tube and leaves the uterus and the opposite ovary alone, because these tumours are usually one-sided and respond so well to chemotherapy that heroic surgery buys nothing.
This holds even where the disease has spread beyond the ovary, which surprises many families. Menstrual periods usually return after treatment and pregnancy afterwards is common. We cover what is known in detail on fertility after a germ cell tumour.
Because they grow fast and cause symptoms early, a majority are confined to one ovary at diagnosis — the opposite of the usual ovarian cancer story, where disease has typically spread across the abdomen before anything is noticed.
Staging still matters, and it is done at the time of surgery by inspecting the abdomen and taking samples rather than by a separate operation later. That surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there; it is worth knowing in advance who is operating and where.
Where chemotherapy is needed, it is a fixed course of platinum-based combination treatment rather than the open-ended sequence familiar from advanced epithelial disease. It is intensive while it runs, and then it finishes. Anti-sickness care, fertility counselling and support through the course matter as much as the drugs themselves at this age.
Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, which for a young woman still in college or a first job usually means treatment closer to home. How ovarian cancer treatment is organised at CION.
For selected stage I tumours that have been completely removed — a dysgerminoma confined to one ovary, or a low-grade immature teratoma — careful surveillance with regular tumour markers and imaging is an accepted alternative to immediate chemotherapy. The tumour is watched instead of treated, and chemotherapy is held in reserve.
This is only reasonable where follow-up will genuinely happen: the appointments and blood tests are the treatment. If travel, cost or distance make reliable monitoring unlikely, that is worth saying out loud when the choice is being made rather than afterwards.
Occasionally a mass enlarges during or after chemotherapy while AFP and beta-hCG are falling or already normal. This is a recognised phenomenon known as growing teratoma syndrome: the chemotherapy has killed the malignant cells and left behind mature, benign teratoma tissue that continues to expand.
It matters because the answer is surgery to remove it, not more chemotherapy — more chemotherapy will not shrink mature tissue. Knowing that the marker trend and the scan can disagree, and what it means when they do, prevents a good outcome being mistaken for a failing one.
None of these means cancer. Each is a reason to be seen this week rather than rescanned in six months — and a reason for the right bloods to be sent before any surgery is booked.
Germ cell tumours are usually solid or mixed on ultrasound rather than a clear fluid-filled cyst. A solid ovarian mass under 40 deserves specialist assessment.
Enlargement over weeks is characteristic. A visibly bigger mass should not be watched again without markers and a specialist opinion first.
These tumours can twist on their blood supply. Severe pain with vomiting is an emergency — go to a hospital, do not wait for an appointment.
Under 40, AFP, beta-hCG and LDH are the tests that matter. A normal CA-125 on its own does not rule a germ cell tumour out.
Some of these tumours make beta-hCG. A positive test with an empty uterus on scan needs urgent assessment rather than reassurance.
A few of these tumours make hormones. Early puberty in a girl, or periods stopping alongside a pelvic mass, should be investigated quickly.
If surgery has already been arranged elsewhere, ask one question before it happens: have AFP, beta-hCG and LDH been sent? A pre-operative baseline is easy to obtain now and impossible to reconstruct later.
These tumours are uncommon enough that they are not seen often outside specialist practice, and the decisions taken in the first fortnight — which markers were sent, which surgery is planned, whether chemotherapy is needed at all — shape everything afterwards.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the scan, the blood results and the pathology report if there is one — those three documents answer most of the questions people arrive with.
The sequence is fairly predictable, and knowing it takes some of the fear out of the first fortnight — which is when most of the decisions that matter are made.
AFP, beta-hCG and LDH, ideally drawn before any operation. They help point to the tumour type before the pathology is back, and the pre-operative level becomes the benchmark against which everything afterwards is judged. CA-125 may be added, but on its own it answers the wrong question in a young woman.
Pelvic ultrasound first: it shows whether the mass is solid, how big it is, and whether the other ovary is involved. Where a malignant germ cell tumour is suspected, a CT of the chest, abdomen and pelvis defines whether anything has spread before surgery is planned.
The standard operation removes the affected ovary and fallopian tube, inspects the abdomen and takes staging samples, and leaves the uterus and the opposite ovary alone. This surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — CION arranges it and stays involved rather than performing it in-house.
Three things on it drive everything afterwards: the exact tumour type, the grade where it is an immature teratoma, and the stage. Together they answer whether chemotherapy is needed at all, and if so what the course looks like. Ask for a copy — it is your document.
Most malignant germ cell tumours beyond the earliest stage are treated with a fixed course of platinum-based combination chemotherapy, delivered in-house at CION across 35+ centres. Selected completely resected stage I tumours can instead be monitored closely, with chemotherapy held in reserve.
Whichever route is taken, follow-up runs on serial AFP, beta-hCG and LDH alongside imaging, closely at first and then further apart. Periods usually return and fertility is usually retained; what is known about fertility afterwards is worth reading before treatment rather than after it.
*Surgery, including staging and any fertility-sparing procedure, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Chemotherapy, supportive care and long-term follow-up are delivered in-house at CION.
These tumours are uncommon, and that is the practical problem. A general gynaecology clinic may see one every few years, so the young woman in front of it is frequently managed with the reflexes built for a fifty-five-year-old with epithelial disease — a CA-125 and nothing else, or an operation planned before the right bloods have been drawn.
Your first consultation at CION is free and runs to about 45 minutes, which is long enough to go through the scan, the blood results and the pathology report line by line and say what each one actually means. If surgery has not yet happened, the most useful thing that visit can do is make sure the pre-operative markers are sent and the right operation is planned. If it has, the questions become type, grade, stage, and whether chemotherapy is genuinely needed.
Chemotherapy, supportive care and long-term follow-up are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, with genetic counselling available where the history warrants it. Surgery — including staging and fertility-sparing procedures — is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. We would rather be plain about that now than have you discover it at the billing counter.
Free and unhurried. Long enough to read the scan, the markers and the pathology report together and explain what each one changes.
Uncommon tumours are exactly where a single opinion is least reliable. Every case that raises a question is reviewed by the group.
35+ centres across Telangana and Andhra Pradesh, so a course of treatment does not have to mean months away from college or work.
Chemotherapy and follow-up in-house; surgery coordinated with specialist partner centres and possibly billed there. Said upfront.
Search for ovarian cancer survival and the figures that come back are sobering. They are also, for a young woman with a germ cell tumour, close to meaningless. Those numbers are averaged across all ovarian cancer, and they are dominated by advanced epithelial disease in older women, because that is the overwhelming majority of cases.
A germ cell tumour is a different disease with a different natural history: younger patient, usually earlier stage, and a tumour biology that responds to chemotherapy in a way epithelial cancer generally does not. Published figures that mix the two together — often gathered over decades during which treatment changed substantially — will understate the outlook here rather than overstate it. That is why we have not put a number on this page. The meaningful conversation is about your tumour type, its grade and its stage, with the oncologist who has your report in front of them.
For completeness, and because we publish it everywhere rather than only where it flatters: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That pair covers all ovarian cancer and all stages, is a one-year figure rather than a cure rate, and — for the reasons above — is not the number that describes a germ cell tumour.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population, all types and stages.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Both are averages dominated by advanced epithelial disease in older women — a different cancer with a different response to treatment.
*One-year survival rates across all ovarian cancer types and stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals, and averaged ovarian cancer figures are a particularly poor guide in germ cell tumours — discuss the outlook for your own tumour with your treating oncologist.
It is a tumour that begins in the primordial germ cells of the ovary — the cells that would have become eggs — rather than in the surface lining, which is where the ovarian cancer most people have heard of starts. The group includes dysgerminoma, yolk sac tumour, immature teratoma, embryonal carcinoma, non-gestational choriocarcinoma and mixed forms, along with the benign mature cystic teratoma or dermoid cyst. They occur overwhelmingly in girls, adolescents and women in their twenties, they grow quickly, and they are usually still confined to one ovary when they are found. They also secrete different substances from epithelial cancers, which is why the blood tests used to track them are different.
No, and this is the commonest source of unnecessary fear. The mature cystic teratoma, better known as a dermoid cyst, is a germ cell tumour and it is benign. It is by far the commonest tumour in this family, it does not spread, and it is removed only if it is large, painful or at risk of twisting on its blood supply. No chemotherapy is involved. The malignant members of the family — dysgerminoma, yolk sac tumour, immature teratoma, embryonal carcinoma and choriocarcinoma — are genuinely uncommon. The pathology report is what separates them, so the name written on it is worth reading carefully rather than assuming the worst from the word tumour.
Almost every way that matters. The patient is usually decades younger. The tumour grows over weeks rather than quietly over months, so it is usually found while still inside one ovary instead of after it has spread across the abdomen. CA-125 is often unhelpful, and AFP, beta-hCG and LDH are the markers that count. The surgery is deliberately conservative — the affected ovary and tube come out, the uterus and the other ovary stay. And where chemotherapy is needed, it is a fixed, finite course that these tumours respond to far better than epithelial cancers do. Applying the usual ovarian cancer playbook to a young woman with a germ cell tumour gets several of those decisions wrong.
Usually, yes, and it is planned for from the beginning rather than negotiated as an afterthought. Standard management removes the affected ovary and fallopian tube and leaves the uterus and the opposite ovary in place, and this holds even where the disease has spread beyond the ovary, because these tumours respond so well to chemotherapy that more extensive surgery buys nothing. Periods usually return after treatment finishes, and pregnancy afterwards is common. Where chemotherapy is planned, fertility preservation should still be discussed before it starts, so the options are open rather than theoretical. We go through what is known in detail on our page about fertility after a germ cell tumour.
Not always. For selected stage I tumours that have been completely removed — a dysgerminoma confined to one ovary, or a low-grade immature teratoma — close surveillance with regular tumour markers and imaging is an accepted alternative, with chemotherapy held in reserve if anything changes. Beyond the earliest stage, and for the tumour types that behave more aggressively, a fixed course of platinum-based combination chemotherapy is usual and works well. The three things that decide it are the exact tumour type, the grade where the tumour is an immature teratoma, and the stage. Surveillance is only a sensible choice if the follow-up appointments and blood tests will realistically happen, so distance and cost belong in that conversation.
On serial blood markers and imaging. Whichever markers were raised at diagnosis — AFP, beta-hCG, LDH, or a combination — become the ones that are followed, checked frequently at first and then at widening intervals, alongside scans. A marker that falls as expected after surgery and chemotherapy is one of the clearest signs treatment has done its job. One thing worth understanding in advance: a mass can occasionally enlarge while the markers are normal or falling, which usually reflects benign mature tissue left behind rather than active cancer, and it is dealt with surgically rather than with more chemotherapy. Ask what your markers were at the start, and keep the numbers.
The first consultation is free and runs to about 45 minutes. Bring the scan, the blood results and the pathology report if there is one. Chemotherapy, supportive care and long-term follow-up are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, with genetic counselling available where the history warrants it. Surgery — including staging and fertility-sparing operations — is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board, which matters most for uncommon tumours like these.